ChiPros® - Essential Part of Pharmaceutical Crop Protection Agent Synthesis Dr. Klaus Ditrich
.-.*>•
^
tWl fcv Dr. John Banger
Glen Ternpi in
Dr. Frank Stein
BASF provides customers with easy access to its ChiPros technology, a wide and growing portfolio of chiral intermediates that includes amines, beta-hydroxyacids, aminoalcohols, oxazolidinones, aromatic and aliphatic acids, alcohols and epoxides. Just as important, we provide easy access to our scientists to help our customers to be more successful with their syntheses using this innovative technology. We also stand ready to develop new molecules to satisfy customers' needs.
High Purity Enantlomers Biocataiysis The most important method for production of chiral compounds employs enzymes as natural catalysts. "Optimized over a billion years of evolution, these biocatalysts are highly effective and have high process purity when the reaction is well controlled," said Dr. Klaus Ditrich of BASF Fine Chemicals and Biocataiysis Research in Germany. In 1993, BASF scientists discovered that an enzyme of the lipase family catalyzes reactions between amines and carboxylic acid esters. This process paved the way for the expansion of synthesis techniques that build on biocataiysis. "The big advantage of this process for our customers is the enormous range of potential substrates," said Dr. John Banger of BASF's Chemical Intermediates business in Florham Park, N.J. "With more than 50 optically active variants of this class of substances, BASF is currently the world's leading supplier of chiral amines, with more in the development pipeline. No competing method, such as crystallization or asymmetric hydrogénation, can produce such product diversity." "Biocatalytic processes offer huge advantages, including more effective use of starting materials, less waste product creation, and operation at milder conditions with less energy or lower pressure," said Dr. Rainer Stuermer of BASF's Fine Chemicals and Biocataiysis Research in Germany. "Nature has the best methods for achieving optical purity, and we seek to emulate them."
'Ms. Blauvelt
BASF also employs a new process involving dehydrogenases to facilitate a biological reduction of ketones to chiral alcohols, and the company operates two traditional chemical processes for chiral intermediate production. "Our diversity of methods is a strong advantage for our customers because it enables us to support them in a customized manner," said Dr. Frank Stein of BASF's Intermediates business in North America.
At the same time, we are able to achieve optical purity of up to 99%, which is required in particular in the life science industry." In addition to simplified access, the use of this type of enzyme provides other benefits such as: · robust processes • consistently high quality · high product purity The enzymatic process is highly suitable for producing chiral molecules that contain sensitive functional groups because the reaction takes place in the neutral pH range at room temperature or slightly above. In addition, high pressure, heavy metals or noble metals are not required. BASF currently uses six different proprietary enzymes to produce the chiral intermediates that customers need. "The six enoate reductases we use allow the synthesis of alpha- and beta substituted chiral aldehydes and ketones, substituted succinimides or beta substituted nitro compounds," said Templin. In addition , BASF provides comprehensive advice on the use of these enzymatic processes to customers who are interested, focusing on their relevant processes." This way, BASF always offers a comprehensive solution aimed at ensuring a reliable, efficient supply of the desired chiral compounds. "We respond to every inquiry with an individually customized solution," said Templin."
Improved Possibilities Asymmetric Hydrogénation Asymmetric hydrogénation expands the possibilities for creating the precise chiral intermediates that a customer needs. Increasing demand for single-enantiomer compounds has helped the asymmetric hydrogénation of carbon-oxygen and carbon-carbon double bonds to develop into a valuable industrial production method. Using high throughput screening and access to large ligand libraries, BASF is able to create and test many different catalysts for the asymmetric hydrogénation of potential reaction partners, and thereby create more tailor-made chiral building blocks for customers.
New Enzyme for New ChiPros Dr. Rainer Stuermer
In the past, multi-stage processes were needed to gain access to more unstable chiral intermediates. "Chiral nitro compounds or aldehydes, for example, cannot be obtained by asymmetric hydrogénation," says Glen Templin, Business Development Manager for BASF's Life Science Intermediates business in North America, located in Florham Park. "This is exactly where the enzymes come in. Enoate reductases allow simpler, shorter access to the Chipros™ products, making the entire process more cost-efficient.
New The BASF Intermediates New Business Development unit continues to add resources to provide more to pharmaceutical customers. The latest addition to the team is Kathleen (Katie) Blauvelt, the BASF Customer Care Center representative dedicated to serve pharmaceutical customers, who began her new assignment on January 1, 2007.
Helping Make Products Better™
of Innovation" More information
Π-BASF
More information about the BASF ChiPros line of chiral intermediates can be found at www.thinkchiral.com. More than the parts for higher efficiency and improved purity. Intermediates from BASF for life sciences and lots more. Global. Innovative. Valuable. Reliable.
The Chemical Company
W
